Insurance Readiness for Pilot, Clinical, and RWE Studies

Insurance should be treated as a study-start prerequisite, not as an administrative item to resolve after operations begin. Pilot, clinical and real-world evidence (RWE) studies can create product, professional, premises, logistics, privacy, contractual and participant-injury exposures before the first patient is enrolled.

Coverage should therefore be confirmed before investigational or study devices are shipped, a site is activated or any participant-facing activity begins.

Coverage Depends on the Study Model

The required insurance structure depends on the study design and the parties involved. A sponsor may need clinical-trial liability or participant-injury coverage in addition to product liability and commercial general liability insurance.

Sites, contract research organizations, laboratories, home-health providers, logistics companies and other service providers may carry their own policies, but those policies do not automatically protect the sponsor or manufacturer.

Risk allocation should remain consistent across the protocol, clinical trial agreement, vendor contracts, indemnification provisions and insurance certificates.

Shipment Can Trigger Insurance Exposure

Exposure begins as soon as investigational devices leave controlled inventory. Risks may include loss, damage, temperature excursion, unauthorized use, improper storage and injury during setup or training.

Coverage should define who bears responsibility while products are in transit, held at a depot, stored at a clinical site or placed in a participant's home.

Product liability policies should also be reviewed for exclusions involving investigational use, unapproved indications, clinical research or products that have not yet been commercially released.

Verify Insurance Before Site Activation

Site activation should not proceed simply because regulatory and operational documentation is complete.

The study team should verify policy limits, territorial scope, named insureds, additional-insured requirements, insurer ratings where contractually required, deductibles or self-insured retentions, and the period during which claims may be reported.

For claims-made policies, retroactive dates and tail coverage may be especially important because participant claims can arise after study completion.

RWE Studies May Create Different Risks

Real-world evidence studies require the same discipline as traditional clinical investigations. Although the device may already be cleared or approved, the protocol, data-collection methods, patient interactions, off-label use, remote monitoring or direct-to-patient supply model may create risks outside ordinary commercial operations.

Existing commercial insurance should therefore be evaluated against the actual study activities rather than assumed to apply.

Align Insurance With Operational Readiness

MDD Studies can help sponsors map study activities, product flows, site responsibilities and vendor roles before launch so insurance questions are identified early.

Working alongside the sponsor's insurance broker, legal counsel and study team, MDD Studies helps align shipment controls, site activation criteria, contractual responsibilities and evidence of coverage with the operational realities of the study.